• Sarepta Therapeutics Inc (NASDAQ: SRPT) shared new analyses and functional data from its SRP-9001 development program and the details of Study SRP-9001-301 (EMBARK) Phase 3 trial of SRP-9001 for Duchenne muscular dystrophy.

• SRP-9001, being developed in partnership with Roche Holdings AG (OTC: RHHBY), is an investigational gene transfer therapy intended to deliver its micro-dystrophin-encoding gene to muscle tissue.

• In new analyses of study 101 (n=4, ages 4 to 7), SRP-9001 treated participants improved 8.6 points on the North Star Ambulatory Assessment (NSAA) compared to a matched natural history cohort three years following a single administration of SRP-9001.

• In Study 102, SRP-9001 treated participants ages 6 to 7 (n=12) had a positive 2.9-point difference on NSAA change from baseline compared to a matched natural history control.

• The first 11 participants in Cohort 1, ages 4 to 7, demonstrated a 3.0-point improvement from baseline on NSAA six months after treatment.

• Related: Sarepta's Stock Trading Higher As Duchenne Muscular Dystrophy Gene Therapy Shows Promise In Open-Label Study.

• Price Action: SRPT shares are down 6.62% at $92.84 during the market session on the last check Monday.

See more from Benzinga

• Click here for options trades from Benzinga

• Sarepta, Codiak Nix Exosome Therapy Development Pact

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.